Abstract:OBJECTIVE:To evaluate the feasibility of imatinib reintroduction in gastrointestinal stromal tumor(GIST) with high recurrence risk after imatinib adjuvant therapy failure.METHODS:Clinical and follow-up data of 24 recurrent GIST patients with high recurrence risk receiving imatinib standard dose reintroduction(400 mg/d or 600 mg/d) after stopping imatinib adjuvant treatment more than 3 months in Department of GI Oncology of Peking University Cancer Hospital from August 2005 to January 2016 were retrospectively analyzed. The objective response rate(ORR), relapse-free survival(RFS) of imatinib reintroduction were evaluated and the difference of efficacy in patients receiving different imatinib adjuvant therapy duration were compared.RESULTS:Of 24 patients, 21 were male and 3 were female. The median age was 53 years(39-72 years). Mutation detection of tumor tissues before imatinib therapy showed 20 patients had c-Kit exon 11 mutation,3 patients exon 9 mutation and 1 patient c-Kit/PDGFRA wild type mutation. The median recurrence time was 14 months in all the patients (95%CI:7.9-20.0) and in those patients receiving imatinib adjuvant therapy for 1 or 2 years (9 patients in each group, 95%CI:11.1-16.9 and 8.2-19.8 respectively). The median recurrence time of 3 patients receiving imatinib adjuvant therapy for 3 years was 24, 41 and 54 months respectively. Of 2 patients receiving imatinib adjuvant therapy for 5 years, the median recurrence time was 4 and 18 months. Only one patient received imatinib adjuvant therapy for 6 years, and the recurrence time was 6 months. Twenty patients with exon 11 mutation and 1 patient with wide type received imatinib treatment at a dose of 400 mg daily, and 3 patients with exon 9 mutation received the dosage of 600 mg per day. Among the patients receiving imatinib reintroduction, 11 patients(45.8%) got partial response(PR), 12 patients(50.0%) had stable disease and 1 patient had progression disease. The response rate in patients receiving imatinib adjuvant therapy for 1 year(6/9, 67%) was significantly higher than that in patients receiving adjuvant therapy for ≥2 years(3/15, 20%)(P=0.036). The median progression-free survival (PFS) of imatinib reintroduction was 31 months in all the patients(95%CI:23.6-38.4). The median PFS in patients receiving imatinib adjuvant therapy for 1 year(9 cases), 2 years (9 cases) and ≥3 years (6 cases) was 50 months(95%CI:27.3-72.7), 26 months(95%CI:10.7-41.3) and fall short of median PFS. No significant difference was observed among three groups(P=0.295).CONCLUSIONS:Imatinib reintroduction is still effective to GIST after imatinib adjuvant therapy failure. The different imatinib adjuvant therapy duration can influence the benefit of imatinib reintroduction.

Treatment Patterns, Prescribing Decision Drivers, and Predictors of Complete Response Following Disease Recurrence in Gastrointestinal Stromal Tumor Patients—a Chart Extract-Based Approach

To Compare the Efficacy of Sunitinib and Imatinib Following Cytoreductive Resection in GIST Patients with Progression on Imatinib: A Multi-Center Controlled Study.

Prescribing Decision Drivers in Patients with Recurrent Gastrointestinal Stromal Tumor (GIST) Previously Treated with Adjuvant Imatinib: A Retrospective Chart Extract-Based Approach.

Cytoreductive Surgery for Metastatic Gastrointestinal Stromal Tumors Followed by Sunitinib Compared to Followed by Imatinib-a Multi-Center Cohort Study

Risk of Disease Recurrence and Mortality in Gastrointestinal Stromal Tumor (gist) Patients Receiving Short-Term Versus Long-Term Imatinib Adjuvant Therapy: A Chart Review Analysis.

Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor.

Investigation Of Gastrointestinal Stromal Tumor (Gist) Care Management In Gist Patients (Pts) Receiving Short-Term Versus Long-Term Imatinib (Im) Adjuvant Therapy: A Chart Review Analysis.

Real World Treatment Patterns of Gastrointestinal Stromal Tumor Patients

Comparison of the Long-Term Risk of Recurrence and Other Clinical Outcomes in GIST Patients Receiving Imatinib As Adjuvant Therapy—A Retrospective Chart Extract-Based Approach

Adjuvant imatinib in high‐risk resected gastrointestinal stromal tumors: Merely delaying the inevitable?

Efficacy and safety of adjuvant post-surgical therapy with imatinib in gastrointestinal stromal tumor patients with high risk of recurrence: interim analysis from a multicenter prospective clinical trial]

Association Between Risk of Recurrence Assessment and Adjuvant Treatment (tx) Duration in Patients (pts) with Resected Gastrointestinal Stromal Tumors (Gists)

Complete Response of Advanced Rectal Gastrointestinal Stromal Tumors after Imatinib Treatment: A Case Report and Literature Review

Clinical Outcomes of Imatinib Dose Escalation Versus Sunitinib in First-Line Imatinib-Failure Gastrointestinal Stromal Tumour

Characteristics and predictors of outcomes with neoadjuvant imatinib in gastrointestinal stromal tumors: Real-world data from a large patient registry.

SKP2 High Expression, KIT Exon 11 Deletions, and Gastrointestinal Bleeding As Predictors of Poor Prognosis in Primary Gastrointestinal Stromal Tumors.

[Efficacy Observation on Imatinib Reintroduction in Gastrointestinal Stromal Tumor with High Recurrence Risk after Imatinib Adjuvant Therapy Failure].

KITlow Cells Mediate Imatinib Resistance in Gastrointestinal Stromal Tumor

Characteristics of Gastrointestinal Stromal Tumor (GIST) Patients Receiving Short-Term Versus Long-Term Imatinib (IM) Adjuvant Therapy: A Chart Review Analysis.

A systematic review and meta‐analysis of neoadjuvant imatinib use in locally advanced and metastatic gastrointestinal stromal tumors

Genomic Subtypes of GISTs for Stratifying Patient Response to Sunitinib following Imatinib Resistance: A Pooled Analysis and Systematic Review